224 related articles for article (PubMed ID: 22310711)
1. The nucleotide-binding domain of NLRC5 is critical for nuclear import and transactivation activity.
Meissner TB; Li A; Liu YJ; Gagnon E; Kobayashi KS
Biochem Biophys Res Commun; 2012 Feb; 418(4):786-91. PubMed ID: 22310711
[TBL] [Abstract][Full Text] [Related]
2. The balance between nuclear import and export of NLRC5 regulates MHC class I transactivation.
Zhu B; Ouda R; An N; Tanaka T; Kobayashi KS
J Biol Chem; 2024 May; 300(5):107205. PubMed ID: 38519032
[TBL] [Abstract][Full Text] [Related]
3. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.
Meissner TB; Li A; Biswas A; Lee KH; Liu YJ; Bayir E; Iliopoulos D; van den Elsen PJ; Kobayashi KS
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13794-9. PubMed ID: 20639463
[TBL] [Abstract][Full Text] [Related]
4. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.
Vijayan S; Sidiq T; Yousuf S; van den Elsen PJ; Kobayashi KS
Immunogenetics; 2019 Mar; 71(3):273-282. PubMed ID: 30706093
[TBL] [Abstract][Full Text] [Related]
5. NLRC5 cooperates with the RFX transcription factor complex to induce MHC class I gene expression.
Meissner TB; Liu YJ; Lee KH; Li A; Biswas A; van Eggermond MC; van den Elsen PJ; Kobayashi KS
J Immunol; 2012 May; 188(10):4951-8. PubMed ID: 22490869
[TBL] [Abstract][Full Text] [Related]
6. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
Ludigs K; Seguín-Estévez Q; Lemeille S; Ferrero I; Rota G; Chelbi S; Mattmann C; MacDonald HR; Reith W; Guarda G
PLoS Genet; 2015 Mar; 11(3):e1005088. PubMed ID: 25811463
[TBL] [Abstract][Full Text] [Related]
7. NLRC5: a newly discovered MHC class I transactivator (CITA).
Meissner TB; Li A; Kobayashi KS
Microbes Infect; 2012 Jun; 14(6):477-84. PubMed ID: 22209772
[TBL] [Abstract][Full Text] [Related]
8. Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5.
Chelbi ST; Dang AT; Guarda G
Adv Immunol; 2017; 133():89-119. PubMed ID: 28215281
[TBL] [Abstract][Full Text] [Related]
9. CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression.
Downs I; Vijayan S; Sidiq T; Kobayashi KS
Biofactors; 2016 Jul; 42(4):349-57. PubMed ID: 27087581
[TBL] [Abstract][Full Text] [Related]
10. The N-terminal domain of NLRC5 confers transcriptional activity for MHC class I and II gene expression.
Neerincx A; Jakobshagen K; Utermöhlen O; Büning H; Steimle V; Kufer TA
J Immunol; 2014 Sep; 193(6):3090-100. PubMed ID: 25127861
[TBL] [Abstract][Full Text] [Related]
11. Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins.
Robbins GR; Truax AD; Davis BK; Zhang L; Brickey WJ; Ting JP
J Biol Chem; 2012 Jul; 287(29):24294-303. PubMed ID: 22645137
[TBL] [Abstract][Full Text] [Related]
12. MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
Cho SX; Vijayan S; Yoo JS; Watanabe T; Ouda R; An N; Kobayashi KS
Immunology; 2021 Mar; 162(3):252-261. PubMed ID: 32633419
[TBL] [Abstract][Full Text] [Related]
13. NLRC5 controls basal MHC class I gene expression in an MHC enhanceosome-dependent manner.
Neerincx A; Rodriguez GM; Steimle V; Kufer TA
J Immunol; 2012 May; 188(10):4940-50. PubMed ID: 22490867
[TBL] [Abstract][Full Text] [Related]
14. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
[TBL] [Abstract][Full Text] [Related]
15. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V
Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
[TBL] [Abstract][Full Text] [Related]
16. FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.
Kasuga Y; Ouda R; Watanabe M; Sun X; Kimura M; Hatakeyama S; Kobayashi KS
Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2218955120. PubMed ID: 37279268
[TBL] [Abstract][Full Text] [Related]
17. NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.
Staehli F; Ludigs K; Heinz LX; Seguín-Estévez Q; Ferrero I; Braun M; Schroder K; Rebsamen M; Tardivel A; Mattmann C; MacDonald HR; Romero P; Reith W; Guarda G; Tschopp J
J Immunol; 2012 Apr; 188(8):3820-8. PubMed ID: 22412192
[TBL] [Abstract][Full Text] [Related]
18. NLRC5: a key regulator of MHC class I-dependent immune responses.
Kobayashi KS; van den Elsen PJ
Nat Rev Immunol; 2012 Dec; 12(12):813-20. PubMed ID: 23175229
[TBL] [Abstract][Full Text] [Related]
19. Expression regulation and function of NLRC5.
Yao Y; Qian Y
Protein Cell; 2013 Mar; 4(3):168-75. PubMed ID: 23483478
[TBL] [Abstract][Full Text] [Related]
20. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.
Yao Y; Wang Y; Chen F; Huang Y; Zhu S; Leng Q; Wang H; Shi Y; Qian Y
Cell Res; 2012 May; 22(5):836-47. PubMed ID: 22491475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
